Vedolizumab 300 MG Injection [Entyvio]

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Immune Checkpoint Inhibitor-Related Colitis

Drug Information

Target Indication

Immune Checkpoint Inhibitor-Related Colitis

Clinical Trial

Last updated: 8/18/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

TKPHF

TAKEDA PHARMACEUTICAL CO LTD

Related Pipeline

Gastric Ulcer

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

Uterine Fibroids

Plaque Psoriasis

Ulcerative Colitis

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts